Neos Therapeutics (NASDAQ:NEOS) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a hold rating to a buy rating in a report published on Thursday, Zacks.com reports. They currently have $1.50 price target on the stock.
According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an overweight rating and set a $130.00 price target (up previously from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. ValuEngine cut shares of Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Neos Therapeutics currently has a consensus rating of Hold and a consensus price target of $6.88.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The firm had revenue of $14.63 million for the quarter, compared to analyst estimates of $14.20 million. As a group, research analysts expect that Neos Therapeutics will post -0.61 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of NEOS. Rhumbline Advisers increased its stake in Neos Therapeutics by 52.4% in the fourth quarter. Rhumbline Advisers now owns 37,442 shares of the company’s stock valued at $62,000 after acquiring an additional 12,871 shares during the last quarter. BlackRock Inc. increased its stake in Neos Therapeutics by 28.8% in the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock valued at $4,510,000 after acquiring an additional 610,660 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Neos Therapeutics by 58.4% in the fourth quarter. Bank of New York Mellon Corp now owns 119,063 shares of the company’s stock valued at $196,000 after acquiring an additional 43,877 shares during the last quarter. GSA Capital Partners LLP bought a new position in Neos Therapeutics in the fourth quarter valued at $66,000. Finally, Northern Trust Corp increased its stake in Neos Therapeutics by 71.9% in the fourth quarter. Northern Trust Corp now owns 514,618 shares of the company’s stock valued at $849,000 after acquiring an additional 215,241 shares during the last quarter. Institutional investors own 54.87% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.